MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR T cell therapy program for autoimmune diseases.

What makes the human brain unique? A Yale study unlocks new insights into genetic changes that shaped our evolution.

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and complex class of genetic ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

Jones Trading initiated coverage on ProQR Therapeutics N.V. (NASDAQ:PRQR) with a Buy rating and set a price target of $11.00, representing significant upside from the current price of $2.19. The ...

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Slashing indirect-cost funding to 15 percent would mean that “work to cure and treat human disease will grind to a halt,” the ...